FORTRESS MODE KRAS/SMAD4/CDKN2A · Fortress Mode KRAS G12D (90%) / TP53 / SMAD4 / CDKN2A γ₁ = 14.134725141734693 · PDAC · KRAS G12C · SMAD4 · CA19-9 · stroma · fi CANCER BOARD NEURO
PDAC · PANCREATIC
Driver
KRAS G12D (90%) / TP53 / SMAD4 / CDKN2A
Coverage
~13/100k · 5yr survival ~12%
Confidence
SORRY
Open Sorries
⚠ KRAS G12D no approved inhibitor
⚠ Stroma barrier — drug penetration
⚠ Immunologically cold — checkpoint fails
HYPOTHESIS
BRCA1/2-mut subtype → PARP-i. KRAS G12D inhibitors (BI-1701963) in early trials. Stroma targeting preclinical.
⚠ OPEN: KRAS G12D direct inhibition — stroma penetration no approved pathway
3Sorries
γ₁14.134725141734693
CATAN CANCER · PANCREATIC